<DOC>
	<DOCNO>NCT01270347</DOCNO>
	<brief_summary>Patients cystic fibrosis ( CF ) suffer chronic infection low respiratory tract cause one multiple bacteria , include Pseudomonas aeruginosa , particularly problematic eradicate implicate major cause morbidity mortality CF patient . Aerosol delivery antibiotic directly lung increase local concentration antibiotic site infection result improve antimicrobial effect compare systemic administration . Bacterial resistance current aerosol antibiotic treatment indicate need improved therapy treat CF patient pulmonary infection cause multi-drug resistant Pseudomonas aeruginosa bacteria . High concentration MP-376 deliver directly lung project antimicrobial effect even resistant organism .</brief_summary>
	<brief_title>Trial Aeroquin Versus Tobramycin Inhalation Solution ( TIS ) Cystic Fibrosis ( CF ) Patients</brief_title>
	<detailed_description>This study assess comparative safety MP-376 ( Aeroquin ) Tobramycin Inhalation solution ( TIS ) [ TOBI® Novartis Pharmaceuticals ] three consecutive cycle 28-days treatment follow 28-days stable CF patient chronic P. aeruginosa lung infection . Efficacy data MP-376 TIS end first 28-day treatment period also compare , well explored multiple treatment cycle . Study patient participate Mpex 209 give option participate six-month open label extension phase Mpex 209 protocol . The open label extension allow enrolled patient receive three additional course MP-376 ( levofloxacin inhalation solution , Aeroquin™ ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Inclusion Criteria ( select ) : &gt; 12 year age Confirmed Diagnosis Cystic Fibrosis Positive sputum culture P. aeruginosa within past 12 month Patients able elicit FEV1 &gt; /= 25 % &lt; /= 85 % predict value screen Have receive least 3 course inhale tobramycin precede 12 month Clinically stable change health status within last 28 day Able reproducibly produce sputum perform spirometry Exclusion Criteria ( select ) : Use nebulized systemic antibiotic within 28 day prior baseline History hypersensitivity fluoroquinolones inhale systemic aminoglycosides include tobramycin excipients Evidence acute upper within 10 day low respiratory infection within 28 day prior dose CrCl &lt; 20 Screening History lung transplantation Extension Portion Study : Patients enrol Mpex 209 permit participate open label extension long complete Visit 7 ( Day 168 ) , provide inform consent participation open label extension study clinically stable , assessed Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>